ARMP
Income statement / Annual
Last year (2025), Armata Pharmaceuticals Inc's total revenue was $4.90 M,
a decrease of 5.22% from the previous year.
In 2025, Armata Pharmaceuticals Inc's net income was -$173.80 M.
See Armata Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$4.90 M |
$5.17 M |
$4.53 M |
$5.51 M |
$4.47 M |
$823.00 K |
$0.00 |
$0.00 |
$115.00 K |
$260.00 K |
| Cost of Revenue |
$1.53 M
|
$34.43 M
|
$972.00 K
|
$35.02 M
|
$20.02 M
|
$14.44 M
|
$1.35 M
|
$1.35 M
|
$374.00 K
|
$369.00 K
|
| Gross Profit |
$3.37 M
|
-$29.25 M
|
$3.56 M
|
-$29.51 M
|
-$15.54 M
|
-$13.62 M
|
-$1.35 M
|
-$1.35 M
|
-$259.00 K
|
-$109.00 K
|
| Gross Profit Ratio |
0.69
|
-5.65
|
0.79
|
-5.36
|
-3.47
|
-16.55
|
0
|
0
|
-2.25
|
-0.42
|
| Research and Development Expenses |
$23.72 M
|
$34.43 M
|
$33.77 M
|
$35.02 M
|
$20.02 M
|
$14.44 M
|
$9.82 M
|
$4.89 M
|
$2.88 M
|
$5.68 M
|
| General & Administrative Expenses |
$12.41 M
|
$13.18 M
|
$0.00
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$0.00
|
$5.70 M
|
$7.59 M
|
$8.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.41 M
|
$13.18 M
|
$10.68 M
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$7.91 M
|
$5.70 M
|
$7.59 M
|
$8.41 M
|
| Other Expenses |
-$1.53 M
|
-$34.43 M
|
$0.00
|
-$35.02 M
|
-$20.02 M
|
-$14.44 M
|
$0.00
|
-$1.40 M
|
$6.00 K
|
-$554.00 K
|
| Operating Expenses |
$34.60 M
|
$13.18 M
|
$44.45 M
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$17.74 M
|
$9.54 M
|
$16.27 M
|
$23.64 M
|
| Cost And Expenses |
$36.13 M
|
$47.61 M
|
$45.42 M
|
$42.45 M
|
$28.30 M
|
$22.41 M
|
$19.09 M
|
$10.59 M
|
$15.46 M
|
$23.64 M
|
| Interest Income |
$388.00 K
|
$697.00 K
|
$179.00 K
|
$29.00 K
|
$5.00 K
|
$28.00 K
|
$96.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$16.59 M
|
$10.74 M
|
$2.63 M
|
$29.00 K
|
$64.00 K
|
$628.00 K
|
$931.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.53 M
|
$1.33 M
|
$972.00 K
|
$892.00 K
|
$1.17 M
|
$1.11 M
|
$1.35 M
|
$1.35 M
|
$374.00 K
|
$369.00 K
|
| EBITDA |
-$29.69 M |
-$41.11 M |
-$65.45 M |
-$36.05 M |
-$21.92 M |
-$20.44 M |
-$17.20 M |
-$9.54 M |
-$9.98 M |
-$13.46 M |
| EBITDA Ratio |
-6.05
|
-7.95
|
-14.45
|
-6.55
|
-4.9
|
-24.83
|
0
|
0
|
-86.8
|
-51.78
|
| Operating Income Ratio |
-6.37
|
-8.2
|
-9.03
|
-6.71
|
-5.32
|
-26.23
|
0
|
0
|
-140.49
|
-89.92
|
| Total Other Income/Expenses Net |
-$142.58 M
|
$23.52 M
|
-$28.16 M
|
$29.00 K
|
$667.00 K
|
-$594.00 K
|
-$390.00 K
|
$956.00 K
|
$2.02 M
|
$3.98 M
|
| Income Before Tax |
-$173.80 M
|
-$18.92 M
|
-$69.05 M
|
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$16.70 M
|
-$14.14 M
|
-$19.39 M
|
| Income Before Tax Ratio |
-35.44
|
-3.66
|
-15.25
|
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
-122.96
|
-74.59
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$328.00 K
|
-$1.30 M
|
-$556.00 K
|
| Net Income |
-$173.80 M
|
-$18.92 M
|
-$69.05 M
|
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$12.11 M
|
-$12.84 M
|
-$18.84 M
|
| Net Income Ratio |
-35.44
|
-3.66
|
-15.25
|
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
-111.63
|
-72.45
|
| EPS |
-4.8 |
-0.52 |
-1.91 |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-8.9 |
-28.14 |
-345.8 |
| EPS Diluted |
-4.8 |
-0.52 |
-1.91 |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-8.9 |
-27.34 |
-345.8 |
| Weighted Average Shares Out |
$36.24 M
|
$36.16 M
|
$36.08 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$7.83 M
|
$1.36 M
|
$456.25 K
|
$70.28 K
|
| Weighted Average Shares Out Diluted |
$36.24 M
|
$36.16 M
|
$36.08 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$8.01 M
|
$1.36 M
|
$456.24 K
|
$70.28 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
